FRI145 Prevalence Of Type 2 Diabetes Mellitus And Risk Factors For Its Development In Patients With Primary Aldosteronism
Authors: Araujo-Castro Marta , Paja Fano Miguel , González Boillos Marga , Pla Peris Begoña , Pascual-Corrales Eider , García Cano Ana María , Parra Paola , Martín Rojas-Marcos Patricia , Ruiz-Sanchez Jorge Gabriel , Vicente Delgado Almudena , Gómez Hoyos Emilia , Ferreira Rui , García Sanz Iñigo , Recasens Sala Mònica , San Millan Rebeca Barahona , Picón César María José , Díaz Guardiola Patricia , García González Juan Jesús , Perdomo Carolina M , Manjón Miguélez Laura , García Centeno Rogelio , Rebollo Román Ángel , Gracia Gimeno Paola , Robles Lázaro Cristina , Morales-Ruiz Manuel , Calatayud Gutiérrez María , Andree Furio Collao Simone Simone , Meneses Diego , Sampedro Nuñez Miguel Antonio , Escudero Quesada Verónica , Mena Ribas Elena , Sanmartin Sánchez Alicia , Gonzalvo Diaz Cesar , Lamas Cristina , Hanzu Felicia 
Published: October 2023

Abstract
Disclosure: M. Araujo-Castro: None. M. Paja Fano: None. M. González Boillos: None. B. Pla Peris: None. E. Pascual-Corrales: None. A. García Cano: None. P. Parra: None. P. Martín Rojas-Marcos: None. J. Ruiz-Sanchez: None. A. Vicente Delgado: None. E. Gómez Hoyos: None. R. Ferreira: None. I. García Sanz: None. M. Recasens Sala: None. R. Barahona San Millan: None. M. Picón César: None. P. Díaz Guardiola: None. J. García González: None. C.M. Perdomo: None. L. Manjón Miguélez: None. R. García Centeno: None. Á. Rebollo Román: None. P. Gracia Gimeno: None. C. Robles Lázaro: None. M. Morales-Ruiz: None. M. Calatayud Gutiérrez: None. S. Simone Andree Furio Collao: None. D. Meneses: None. M. Sampedro Nuñez: None. V. Escudero Quesada: None. E. Mena Ribas: None. A. Sanmartin Sánchez: None. C. Gonzalvo Diaz: None. C. Lamas: None. F. Hanzu: None.
Purpose: To evaluate the prevalence of type 2 diabetes mellitus (T2DM) in patients with primary aldosteronism (PA) and the risk factors for its development. Methods: A retrospective multicenter study of PA patients in follow-up in 27 Spanish tertiary hospitals (SPAIN-ALDO Register). Adrenal venous sampling (AVS) was informative of laterality in 128 out of 226 patients and adrenalectomy was performed in 201 patients. Unilateral PA was defined as biochemical cure after adrenalectomy or as a lateralization index in AVS &gt; 2 with ACTH or &gt;3 without ACTH stimulation. Results: Overall, 649 patients with PA were included. Median age was 55.5 (range 27.3-81.6) years, 59.1% were female and 58.5% had hypokalemia at diagnosis. A total of 224 patients were classified as unilateral PA (142 based on biochemical cure after adrenalectomy and 82 based also on AVS results) and 49 as bilateral PA. At diagnosis, 21.2% (n=137) had T2DM and 25 of them had microvascular complications, being diabetic kidney disease the most common (n=19). We identified as risk factors of type 2 diabetes: male sex (OR 2.80 [1.81-4.34], P&lt;0.001), older age (OR 1.05 [1.03-1.07], P&lt;0.001), familiar history of T2DM (OR 4.64 [2.39-8.99]), P&lt;0.001), dyslipidemia (OR 4.05 [2.67-6.14], P&lt;0.001), cardiovascular (OR 1.30 [1.14-1.48], P&lt;0.001) and cerebrovascular disease (OR 1.59 [0.92-2.74], P=0.003), sleep apnea syndrome (SAS) (OR 2.21 [1.34-3.63], P=0.003), higher BMI (OR 1.06 per unit [1.03-1.10], &lt;0.001), hypertension duration (OR 1.04 per year [1.02-1.06], P&lt;0.001) and the number of antihypertensive drugs (OR 1.50 [1.29-1.74], P&lt;0.0001). In the multivariant analysis, all these variables were independent risk factors for T2DM except for SAS, hypertension duration, sex, and BMI. No association was observed with plasma aldosterone concentration, potassium levels, unilaterality of PA or other parameters. No significant differences in the evolution of the glycemic control (fasting plasma glucose and HBA1c) were observed between T2DM who underwent surgery and those medically treated (P&gt;0.05). Conclusion: Type 2 diabetes affects about one quarter of patients with PA and risk factors for its development are common than to the general population. Medical and surgical treatment provide a similar benefit in terms of glucose control in patients with PA and T2DM.
Presentation: Friday, June 16, 2023